683 Capital Management’s Altimmune ALT Stock Holding History

683 Capital Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,000	Closed	-$59.1K	–	173
2023 Q1	$59.1K	Sell	14,000 -3,178	-19%	-$37.8K	﹤0.01%	238
2022 Q4	$283K	Buy	+17,178	New	+$193K	0.02%	134
2021 Q1	–	Sell	-32,678	Closed	-$369K	–	174
2020 Q4	$369K	Buy	+32,678	New	+$385K	0.02%	148

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

683 Capital Management's ALT Position: Q2 2023 in Review

683 Capital Management sold out of Altimmune (ALT) in Q2 2023, closing a stake of 14,000 shares — an estimated $59.1K sold.

683 Capital Management first reported a position in ALT in Q4 2020 and held it in 3 quarters. The position peaked at $369K in Q4 2020. 120 funds tracked by Wall St. Rank hold ALT as of Q2 2023.

683 Capital Management reported no remaining Altimmune position as of Q2 2023 after selling out during the quarter.
683 Capital Management sold 14,000 Altimmune shares in Q2 2023, an estimated $59.1K.
683 Capital Management first reported a position in Altimmune in Q4 2020 and held it in 3 quarters.
683 Capital Management's Altimmune position peaked at $369K in Q4 2020.
120 funds tracked by Wall St. Rank held Altimmune as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.